רווח נקי למניה ב-12 החודשים האחרונים: Coya Therapeutics Inc (COYA)

Coya Therapeutics, Inc. (COYA) is protected by T-cell patents, creating a massive barrier to entry for competitors. The team relies on rare neurodegeneration experts attracted by RSU packages. Financial stability is supported by grants from pharma behemoths. The current TTM EPS time series on the GURU.Markets chart demonstrates stability, where the -1.32 level captures the latest values.
פילוחים אנליטיים ודוחות נתונים של חברת Coya Therapeutics, Inc. (COYA)

Coya Therapeutics, Inc. (COYA) is developing innovative methods to combat neuroinflammation associated with Alzheimer's and Parkinson's diseases. The progress of these developments is reflected in the rolling annual earnings per share. This metric determines the actual equity profit, excluding the impact of one-off transactions by major players. Peak values on the curve may indicate the limit of the asset's fundamental strength. Analyzing this indicator allows an investor to avoid overpaying for the company.